new drug approval process in japan

5
307 New drug approval process in Japan Takao Hayakawa Addresses National Institute of Health Sciences, l-1 8-1, Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan; e-mail: [email protected] Current Opinion in Biotechnology 1999, 10307~311 IF,>Elsevier Science Ltd ISSN 0958-l 669 Abbreviations ADR adverse drug reaction CPAC Central Pharmaceutical Affairs Council GCP Good Clinical Practice ICH International Conference on Harmonization MWH Ministry of Health and Welfare NDA New Drug Application NIH National Institute of Health NIHS National Institute of Health Sciences NIID Natlonal Institute of lnfectlous Diseases PA0 Pharmaceutical Affairs Bureau PAL Pharmaceutical Affairs Law PCD Pharmaceuticals and Cosmetics Division PMDEC Pharmaceuticals and MedIcal Devices Evaluation Center PMSB Pharmaceutical and Medical Safety Bureau Introduction Recently, several new measures have been taken by Japan’s Ministry of Health and Welfare (MHW) to ensure that good quality, safe and effective pharmaceuticals are developed and registered in a more efficient and rational manner. ‘I’hese new measures include: amendments to the Pharmaceutical Affairs Law (the fundamental law regulat- ing drugs) and other related laws: construction of a new system of drug review; and updating technical require- mcnts for new drug registration hased on the achievements of the International Conference on Harmonization (I(:H). ‘I’his paper will describe the current situation in Japan regarding the approval process for new drugs. The legal basis of drug evaluation/registration and review system Pharmaceutical administration in Japan is conducted according to a number of laws. l;or the implementation and management of these laws, detailed regulations are pre- pared by government and ministerial ordinances and notices. and notifications are issued by the Director General of the Bureau of the MIHW or the directors of the Division in charge [ 1,2]. Among these laws and related reg- ulatory documenrs, the Pharmac~cutical Affairs I,aw (PAL) is the supreme law. The purpose of the PAL is to regulate matters pertaining to drugs, including biotechnological/biological products. quasi-drugs, cosmetics, and medical devices, to ensure their quality, efficacy and safety. It also promotes the development of drugs for rare diseases. The principal legal basis of the drug evaluation/registra- tion and review system is described in the PAL. The PAL has been revised several times since it was enacted in 1960 in order to meet, firstly, scientific developments in the pharmaceutical field. secondly, public needs and demand for better quality, safe and effective pharmaceu- ticals, and finally, movement towards international harmonization on technical requirements for the registra- tion of pharmaceuticals [3,4]. Some specific features of revisions of the PAL and ocher related laws, which have recently been made, are as follows 141: 1. ‘l’he amendments strengthened the regulations concern- ing clinical trials performed both for new drug applications (NDAs) and post-marketing surveillance (PMS). Manufacturers are legally required to adhere to Good (Yinical Practice (GCP) regulations, with legal repercus- sions if they do not. ‘I’he legal bases for GCP inspections have also been fortified. At the same time, the Organization for Drug Adverse Drug Reaction (ADR) Relief, Research and Development Promotion and Product Review (the I)rug Organization), a semi-governmental body authorized by MHW3 has been legally empowered to perform consul- tations on clinical trials with the sponsors: 7. Improvement in the Nl)A/I’MS review system; 3. ‘I’he clinical and non-clinical NDA and post marketing data submitted have to meet the legally stipulated stan- dards. ‘I‘his reflects an improvement in the data to meet recent advances in the related sciences that are embodied in the ICH guideline; 4. ‘I’he requirements concerning AI)R reports both during clinical trials and after marketing have been documented. Organizations involved in the new drug application review and restructuring of the review system Japan’s MHW is in charge of improving and promoting social welfare, social security and public health. The MHW consists of home offices and external bodies. The home offices comprise the Minister’s Secretariat, nine Bureaus, local branch offices and affiliated institutions. ITp to 1997, three different organizations were mainly involved in NDA review: firstly, the Pharmaceutical Affairs Bureau (PAR), one of the nine MHW Bureaus; secondly, affiliated institutions of MHW, namely the National Institute of Health Sciences (NIHS) and the National Institute of Health (NIH), which was renamed as the National Institute of Infectious Diseases (NIlD)in 1997; and finally, the Central Pharmaceutical Affairs Council (WAC), an advisory body to the Minister of Health and Welfare, which is composed of experts working in medical and pharmaceutical institutions and universities. ‘The CPAC: examines and reviews important pharmaceutical matters.

Upload: takao-hayakawa

Post on 05-Jul-2016

216 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: New drug approval process in Japan

307

New drug approval process in Japan Takao Hayakawa Addresses National Institute of Health Sciences, l-1 8-1, Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan; e-mail: [email protected]

Current Opinion in Biotechnology 1999, 10307~311

IF,> Elsevier Science Ltd ISSN 0958-l 669

Abbreviations ADR adverse drug reaction

CPAC Central Pharmaceutical Affairs Council

GCP Good Clinical Practice

ICH International Conference on Harmonization

MWH Ministry of Health and Welfare

NDA New Drug Application

NIH National Institute of Health

NIHS National Institute of Health Sciences

NIID Natlonal Institute of lnfectlous Diseases

PA0 Pharmaceutical Affairs Bureau

PAL Pharmaceutical Affairs Law

PCD Pharmaceuticals and Cosmetics Division

PMDEC Pharmaceuticals and MedIcal Devices Evaluation Center

PMSB Pharmaceutical and Medical Safety Bureau

Introduction Recently, several new measures have been taken by

Japan’s Ministry of Health and Welfare (MHW) to ensure that good quality, safe and effective pharmaceuticals are developed and registered in a more efficient and rational manner. ‘I’hese new measures include: amendments to the Pharmaceutical Affairs Law (the fundamental law regulat- ing drugs) and other related laws: construction of a new system of drug review; and updating technical require- mcnts for new drug registration hased on the achievements of the International Conference on Harmonization (I(:H). ‘I’his paper will describe the current situation in Japan regarding the approval process for new drugs.

The legal basis of drug evaluation/registration and review system Pharmaceutical administration in Japan is conducted according to a number of laws. l;or the implementation and management of these laws, detailed regulations are pre- pared by government and ministerial ordinances and notices. and notifications are issued by the Director General of the Bureau of the MIHW or the directors of the Division in charge [ 1,2]. Among these laws and related reg- ulatory documenrs, the Pharmac~cutical Affairs I,aw (PAL) is the supreme law.

The purpose of the PAL is to regulate matters pertaining to drugs, including biotechnological/biological products. quasi-drugs, cosmetics, and medical devices, to ensure their quality, efficacy and safety. It also promotes the development of drugs for rare diseases.

The principal legal basis of the drug evaluation/registra- tion and review system is described in the PAL. The PAL

has been revised several times since it was enacted in 1960 in order to meet, firstly, scientific developments in the pharmaceutical field. secondly, public needs and demand for better quality, safe and effective pharmaceu- ticals, and finally, movement towards international harmonization on technical requirements for the registra- tion of pharmaceuticals [3,4]. Some specific features of revisions of the PAL and ocher related laws, which have recently been made, are as follows 141:

1. ‘l’he amendments strengthened the regulations concern- ing clinical trials performed both for new drug applications (NDAs) and post-marketing surveillance (PMS). Manufacturers are legally required to adhere to Good (Yinical Practice (GCP) regulations, with legal repercus- sions if they do not. ‘I’he legal bases for GCP inspections have also been fortified. At the same time, the Organization for Drug Adverse Drug Reaction (ADR) Relief, Research and Development Promotion and Product Review (the I)rug Organization), a semi-governmental body authorized by MHW3 has been legally empowered to perform consul- tations on clinical trials with the sponsors:

7. Improvement in the Nl)A/I’MS review system;

3. ‘I’he clinical and non-clinical NDA and post marketing data submitted have to meet the legally stipulated stan- dards. ‘I‘his reflects an improvement in the data to meet recent advances in the related sciences that are embodied in the ICH guideline;

4. ‘I’he requirements concerning AI)R reports both during clinical trials and after marketing have been documented.

Organizations involved in the new drug application review and restructuring of the review system Japan’s MHW is in charge of improving and promoting social welfare, social security and public health. The MHW consists of home offices and external bodies. The home offices comprise the Minister’s Secretariat, nine Bureaus, local branch offices and affiliated institutions. ITp to 1997, three different organizations were mainly involved in NDA review: firstly, the Pharmaceutical Affairs Bureau (PAR), one of the nine MHW Bureaus; secondly, affiliated institutions of MHW, namely the National Institute of Health Sciences (NIHS) and the National Institute of Health (NIH), which was renamed as the National Institute of Infectious Diseases (NIlD)in 1997; and finally, the Central Pharmaceutical Affairs Council (WAC), an advisory body to the Minister of Health and Welfare, which is composed of experts working in medical and pharmaceutical institutions and universities. ‘The CPAC: examines and reviews important pharmaceutical matters.

Page 2: New drug approval process in Japan

308 Regulatory affairs

Among these organizations, the PAR - especially the Pharmaceuticals and Cosmetics Division (PCD) within the PAB, which was the regulatoF agency for drug approval - played a central role in the administrative activities for evaluation and registration of new drugs. Although the PCD was engaged in the review of generic over the counter drugs, minor changes in new drug approval as well as in the preliminary review of NDAs, the scientific and medical aspects of the applicar-ions for approval of new pre- scription drugs were reviewed in essence by the members of the various CPAC committees. ‘I’he Minister of Health and Welfare makes the final decision on approval in accor- dance with the CPAC report. In this context, one of the activities of the PAB/PCLl was to act as a secretariat to organize and run the CPAC committees [5,6].

In the NDA review process, the NIHS and NIH/NIID have played roles as national control laboratories for phar- maceuticals by engaging in ‘Special Examinations’ in order to determine if the specifications and testing methods pro- posed for a new drug approval are appropriate. The NIHS deals with nearly all pharmaceuticals other than antibi- ocics, vaccines and some blood products, which are dealt with by the NIH/NIID. Furthermore, the experts from both institutions. especially at the NIHS in the drug clual- it?; and safety fields, have positively supported the PAR acrivities in various ways throllgh their scientific research, testing and investigating to assess the quality. safety and efficacy of pharmaceutical products. Also, many NIHS experts have served as members of the (:PAC and have played a crucial role in their respective special fields.

The CPAC functions to investiggte and discuss, as requested by the Minister of Health and \Velfare. important matters on drugs (including medical devices, quasi-drugs and cosmet- ics). Xlajor subjects of the CPA<: discussion are: revision of the Japanese Pharmacopoeia; eQ&lishment of standards for

drugs and related products; judgement on manufacturing approval for new drugs; determination of the number of drugs designated for efficacy reevaluation and implementa- tion of the efficacy reevaluation; judgement, in light of medic31 and pharmaceutical sciences. on granting the relief fund under the Law of the Organization for L>rug AI1K Relief, Research and Ijesign Promotion and Product Review.

‘I’he (:PA(: has one executive committee, 1.5 committees, and 6.1 subcommittees. Four crlmmittees and 14 sulxo~n-

mittees have been involved in the examination of NDAs. ‘I’he CPA(: subcommittees an(l committees are organized so as to enable the examinatiorl of new drugs according to category and intended clinical DISC. For example, the l;irst Subcommittee on New 1)rugs engages in the examination of hormonal drugs, as well as dri~gs for diseases of digestive organs, kidney, liver, and so on. ‘I‘hus, hormones, such as insulin. glucagon, growth hormone. somatomedin C or atri- al natriuretic polypeptide. erychropoietines as drugs for renal anemia, intcrferons for viral hepatitis, and glucocere- brosidasc for Gaucher’s disease were reviewed by this

subcommittee. Plasminogen activators, such as t-PA, prourokinase and urokinase, were examined by the Second Subcommittee on New Drugs, which deals mainly with circulatory system drugs. When cytokines, such as interfer- ons, colony-stimulating factors, interleukins, or tumor necrosis factor, were submitted for approval as new anti- cancer drugs, they were examined by the Subcommittee on Anticancer Drugs. If their intended clinical uses are other than as anticancer drugs, then their safety and effica-

CY would be reviewed by another appropriate subcommittee. The results of the examination by these subcommittees are usually reconfirmed by the Committee on Drugs and then the Executive Committee. Vaccines, such as hepatitis B surface antigen, are examined by the Subcommittee and Committee on Biological Products and by the Executive Committee. The Committee on Blood Products deals with major components of blood, including blood coagulation factors, but excluding plasminogen acti- vators, kallikreins, hormones, and cytokines. Committees on Biological Products and Blood Products also engage in the standardization of specifications and testing methods for vaccines, blood products, and interferons [S].

Lip to the end of 1998, SO biotechnology-derived prescription drugs have been approved in Japan and several biotechnolo- gy products are presently under review. Among these, 20 products originated and were developed in Japan. Very recently, recombinant glucocerebrosidase, 2nd recombinant blood coagulation factor VIII, 4th recombinant t-PA, a modi- fied recombinant t-PA, interferon gamma from a continuous cell line ((XI,) and CCL-derived hepatitis B surface antigen have been approved as prescription drugs for marketing. The latter three products were discovered in Japan.

In the framework of this Japanese drug approval process, the Japanese Government, to a large extent, has depended on the evaluation of NDAs to the over 500 members of the various CP,4(: committees. This means that the members of each subcommittee who examine, for example, a new biotechnology product according to its intended clinical use would decide on the type, extent, and methods of the preclinical and clinical studies required for the approval of the agent. ‘This might lead, however, to inconsistent regu- latory and scientific policies between subcommittees of the CI-?4C because the subcommittee members are usual- ly different depending on the committee. An important role of the PAB was to coordinate regulatory and scientific policies between the CPA(: subcommittees [7]. although this was sometimes time-consuming.

In order to ensure better and more prompt NDA review within the MHW, or more broadly, to improve the regula- tory system to ensure better quality, safety and efficacy of the drugs, and to avoid too much dependence on as well as make better use of the external advisory council (CPAC), the hlHW restructcd its organization in July 1997. These changes include: restructuring of one of the nine MHW Bureaus that has been responsible for the pharmaceutical

Page 3: New drug approval process in Japan

New drug approval process in Japan Hayakawa 309

administration. that is, reform the PAB to the

Pharmaceutical and Medical Safety Bureau (PMSB): establishment of the Pharmaceuticals and Medical Devices Evaluation Center (PMDEC) within the NIHS; and strengthening of the Drug Organization. This restruc- turing was especially intended to strengthen the government’s evaluation capacity for securing the safety of drugs and preventing ADRs.

‘T’he PMSB consists of six divisions, and for NDA review the Evaluation and L,icensing Division will supervise the overall process and handle polic~y-related matters.

The newly established PMI)EC in the NIHS comprises three divisions initially, increasing to five divisions in April 1999. ‘I’he PMDEC houses more than 60 reviewers with expertise in pharmaceutical sciences, medicine, dentistry, veterinary science, bio-statistics and others, so it is capable of examining and evaluating NI)A dossiers in a more inten- sive and precise manner before consulting with the CI’.4C.

‘I’hc role of the Drug Organisatlon is to support the review by consulting with the sponsors and verifying the source data. ‘I’he latter activity including G(ZP as well as (;ood I,aboratory Practice inspections. and examining other raw data, is legally entrusted by MHW to the L>rug Organization.

The current new drug application review process With the rstahlishmcnt of the I’MDEC:, the NDA review process has boen improved. ‘I’he PMDK accepts, on behalf of the Minister of ITeallh and Welfare, the NDAs suhmittcd and leaves the dat‘l reliability survey to the I>rug Organization. A basic but intensive review is then conducted from the scientific point of view by an in-house evaluation team consisting of pharmacists, physicians, sta- tisticians and other cxpcrts. alld an evaluation report is prepared. ‘I’he report is submitted to the WAC to con- summate the review for appro\a1. ‘T’he aim is to prepare a report :IS complete as poss~hlc so that the WAC: Committee need only discuss critical issues, for example. key points to bc cl-aluated with respect to clinical safety and efficacy of the drug. Iyor th,tt purpose, whenever nec- essary during an in-house evaluation. the PhlDlK review team may consult with the experts from NIHS and other public institutions as well as the: I’hlSB staff. Indeed, the application of new I)iotcchnolog!-derived products will he evaluated jointly by I’MDEC’s review team and experts from the Division of Biological (Chemistry and Biologicals at NIHS before proceeding to the (X’AC.

It should he noted that any person wishing to manufacture or import a new drug, f‘irst has to obtain a manufacturing/import approval followed by a manufactur- er/importer’s license for each item from the hlinistrr of Hcaith and Welfare. ‘[‘he license is issued after the I-‘MSR/~~IHW ensures that the applicant is able to manu- facture/import the approved drug, for example, whether

the manufacturing/business facilities of the applicant have sufficient structure/equipment, manufacturing and quality control methods and human resources to properly deal with the approved drug. Drug manufacturers cannot get a license unless they conform to Good Manufacturing Practice [ 1 ,Z].

Technical requirement for biotechnological/biological products Before the ICI-I, the official regulatory position of the Japanese government concerning biotechnology drugs could be found in two Notifications, PAB/Evaluation and Registration Division Notification no. 243 originally issued in March 1984 and revised in 1992, and PAB/First Evaluation and Registration Division Notification no. 10 issued in June 198X. ‘I’he former describes standard requirements for data to be submitted with applications for approval of recombinant DNA peptide or protein drugs derived from fi,‘:st;llrr~&icr roli or other microorgan- isms. ‘T-he latter covers recombinant DNA drugs derived from mammalian cells, monoclonal antibodies, and any other protein drugs produced by certain cell-culture sys- tems [5,8].

‘I’ogether with progress in the development of ICH-har- monizrd documents, the MHW, of course based on the achievements of the ICH, has been taking the necessary measures to update the technical requirements for new drug registration.

As of March 1999, six internationally harmonized docu- ments have been completed for biotechnological/ biological products. These include Cell Substrate, Genetic Stability. Viral Safety, Product Stability, Specifications and Preclinical Safety documents.

‘I’hc objective of the ‘Cell Substrate’ guideline is to pro- vide broad guidance on appropriate standards for the derivation of human and animal cell lines and microbial cells to be used to prepare hiotechnological/bio~ogica) pro- tein products defined in this document, and for the preparation and characterization of cell banks to be used for production. Some of the important components of the ‘Cell Substrate’ document include: firstly, source, history, and generation of the cell substrate: secondly. cell banking, and finally, characterization and testing of the cell bank.

Biotcchnological/hiological product refers to any- product prepared from cells cultivated from cell banks with the exception of microbial metaholites. such as, for example, antibiotics, amino acids, carbohydrates and other low mol- ecular weight substances. (:ell banks used to prepare gene therapy products or vaccines should follow the recommen- dations presented in this document. For some biological products, such as certain virul vaccines prepared in prima- ry cell cultures derived directly from animal tissues or organs, considerations that may apply to primary cells are discussed further in the Appendix of the document.

Page 4: New drug approval process in Japan

310 Regulatory affairs

‘I’he objective of the ‘Genetic Stability’ guideline is to pro- vide guidance regarding the characterization of the expression construct for the production of recombinant DNA protein products in eukaryotic and prokaryotic cells. The purpose of analyzing the expression construct is to establish that the correct coding sequence of the product has been incorpomted into the host cell and is maintained during culture to the end of production.

‘I‘he ‘Viral Safety’ document i$ concerned with testing and evaluation of the viral safet) of biotechnology products derived from characterized cell lines of human or animal origin (i.e. mammalian, avian, Insect) and outlines data that , should be submitted in the marketing application/registra- tion package. ‘I’he purpose of this document is to provide a general framework for virus testing. experiments for the assessment of viral clearance and a recommended approach for the design of viral tests and viral clearance studies. Major areas described in the viral safety document include: cell line qualification; testing for viruses in unprocessed bulk; a rational<. and action plan for viral cleamnce studies and virus tests on purified bulk; and eval- uation and characterization of viral clearance from unprocessed bulk.

‘I‘he purpose of the ‘Product Stability’ document is to give guidance to applicants regarding the type of stability stud- ies that should be provided in support of marketing applications for hiotechnolo~ical/biolo~ical products in which the active components are typically well-character- ized proteins and/or polypeljtides. The specific areas described in the guideline inc,lude: selection of batches: stability-indicating profile that provides assurance that changes in the identity, purity and potency of the product will be detected; storage conditions; testing frequency; specifications: and labeling.

Bulk drug substance and final product specifications are key parts of the core documentation for world-wide product license applications. ‘l’he ‘Specification’ guide- line provides general principles on the setting and justificarion, as far as is possible, of a uniform set of international specifications for biotechnological/bic,logi- cal products to support new m.lrketing applications. The guideline identifies a number of general principles for consideration in setting specifications: first, characteriza- tion of a product; second, analytical considerations related to reference standards Jnd reference materials as well as validation of analytical procedures; third, process controls; fourth, pharmacopoeia] specifications: fifth, release limits versus shelf-life limits; and sixth. statistical concepts. The document also provides guidance for jus- tification of the specification and drug substance specification and drug product specifications.

The ‘Preclinical Safety’ guidelIne is intended to provide general principles for designing scientifically acceptable preclinical safety evaluation programs. The major

general areas considered in the guideline include: spec- ification of the test materials that are utilized in safety assessment studies; considerations related to assessment of biological activity and pharmacodynamics; unique issues related to selection of animal species or models for pharmacology and toxicity studies; guidance related to the number/gender of animals; consideration related to designing the route, frequency and method of admin- istration of test materials and dose selection; and specific considerations related to immunogenicity of a product. The guideline also describes areas of specif- ic concern.

It should be noted that the Cell Substrate and Genetic Stability documents are related to early stages in the manufacturing process, including banked cell substrates and cells at the limit. that is, production cells cultured up to the proposed limit of drug production runs. Viral Safety issues are related to all stages involved in the manufacturing process. including banked cell substrates, cells at the limit, unprocessed bulk, purified bulk or final product. Product Stability, Specifications and Preclinical Safety ‘I’esting documents are related to purified bulk and/or final products. ‘I’hus. fundamental issues related to technical requirements for the consistent production of biotechnology pharmaceuticals and for their assess- ment and control with respect to quality and preclinical safety have been mainly covered [9,10]. It is suggested that applicants should use these I(:H documents. when- ever possible and appropriate. in place of the existing PAR Notifications.

In addition, because of the nature of drug research and development, especially- in the biotechnology field and the specific features of each product, it will be necessary to adopt a science-based flexible approach upon reviewing an individual application. Also, updating any existing docu- ments based on new and developing scientific data and development of new guidance for NDA concerning novel types of biopharmaceuticals, such as for gene therapy or cellular therapy or transgenic animal-derived products, will be necessary, though MHW has already issued guidance for clinical research for gene therapy. Scientific policies concerning new drug appro\,al will always need to be kept in the front line of research.

Conclusions It is expected that developments in cooperative relation- ships among the PhlSR, PMDEC/NIHS, Drug Organization and CPAC will lead to ensuring smooth and rational processing throughout the administrative and sci- entific drug approval process. It is also expected that pharmaceutical administration will be conducted in an open and transparent manner.

Of course the ultimate goal of this endeavor should be to allow patients increased accessibility to novel safe and effective medicines awaiting approval.

Page 5: New drug approval process in Japan

New drug approval process in Japan Hayakawa 311

References 1.

2.

3.

4.

5.

6.

Pharmaceutrcals and Cosmetics Division, Pharmaceutrcal Affarrs Bureau, Japanese Ministry of Health and Welfare (Eds): Japanese Technical Requirements for New Drug Registration 1997, with Relevant Japanese and ICH Guidelines Collected in an Appendix. Tokyo: Yakuji Nippo Ltd; 1997.

Pharmaceutrcal Affairs Bureau, Japanese Minrstry of Health and Welfare (Eds): Pharmaceutical Administration in Japan fin Japanese and Eng/ish,J, edn 7. Tokyo: Yakuji Nippo Ltd; 1996.

Doi 0: Opening addresses. In Proceedings of the Fourfh lnternafional Conference on /-/armonlzat/on: 1997; Brussels. Edited by D’Arcy PF, Harron DWG. Northern Ireland: Greystone Books Ltd; 1998:21-24.

Tominaga T: The benefits of harmonization. In Proceedings of the Fourth biternational Conference on Harmonization: 1997; Brussels. Edited by D’Arcy PF, Harron DWG. Northern Ireland: Greystone Books Ltd; 1998506-508.

Hayakawa T: The Japanese perspective regarding regulatory concerns for biotechnology drugs and their scientific basis. In Drug Biotechnology Regulation, Scientific Basis and Practices. Edtted by Chiu Y-YH, Gueriguian JL New York: Marcel Dekker Inc; 1991:468-498.

Morrguchr H: Regulatory expectation for data on viral testing and process evaluation for phase 1 studies and product licensing in

7.

8.

9.

10

Japan. In Viral Safety and Evaluation of viral Clearance from B/opharmaceutica/ Products. Developments in Biological Standardization, vol 88. Edited by Brown F, Lubiniecki A. Basel: Karger; 1996:143-l 47.

Hayakawa T: Current regulatory situation in Japan with respect to the preclinical safety testing for biotechnology products intended for human use. In Proceedings of the First fnternational Conference on Harmonization: 1991; Brussels. Edited by D’Arcy PF, Harron DWG. Northern Ireland: Greystone Books Lid; 1992:295-301.

Hayakawa T: Global perspective on specifications for biotechnology products. Perspective from Japan. In Development of Specifications for Biotechnology Products. Developments in Biological Standardization, vol91. Edited by Brown F, Fernandez J. Basel: Karger; 1997:15-23.

Hayakawa T: Technical workshop II: new medicines from biotechnology: workshop overview. In Proceedings of the Fourth fnternational Conference on Harmonization: 1997; Brussels. Edrted by D’Arcy PF, Harron DWG. Northern Ireland: Greystone Books Ltd; 1998:153-156.

Hayakawa T: Overview of the international endeavor toward harmonization of technical requirements for the control of new medicines from biotechnology. In Proceedings of Animal Cell Technology: Challenges for the 27s’ century (JAACUESACT). Edited by lkura K, Nagao M, Masuda S, Sasaki R. Netherlands: Kluwer Academrc Publishers; 1999:215-219.